This three-year rare disease study was being conducted at 75 study sites throughout the United States, Canada, Europe, and Australia. The study required a 13-month commitment from patients and had a rigorous visit calendar for the first three months of treatment, thus the sponsor was seeking assistance with patient travel and coordination.

Get Your Copy Now

When you need direct access to physicians and their known patients or research practice management solutions to accelerate your clinical trials, there’s Only Elligo.

Contact Us